A LONGITUDINAL-STUDY OF GRANULOCYTE-COLONY-STIMULATING FACTOR LEVELS AND NEUTROPHIL COUNTS NEWBORN-INFANTS

被引:12
作者
WILIMAS, JA
WALL, JE
FAIRCLOUGH, DL
DANCY, R
GRIFFIN, C
KARANTH, S
WANG, W
EVANS, WE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT BIOSTAT, MEMPHIS, TN 38101 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT SCI, MEMPHIS, TN 38101 USA
[3] UNIV TENNESSEE, DEPT PEDIAT, CTR PEDIAT PHARMACOKINET & THERAPEUT, MEMPHIS, TN USA
[4] UNIV TENNESSEE, DEPT CLIN PHARM, MEMPHIS, TN USA
[5] CTR HLTH SCI, MEMPHIS, TN USA
关键词
GRANULOCYTE COLONY-STIMULATING FACTOR; NEUTROPHIL COUNTS;
D O I
10.1097/00043426-199505000-00014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The goal of this study was to longitudinally measure endogenous granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) levels in newborn infants and to attempt to correlate these levels with neutrophil counts. Patients and Methods: Samples for complete blood count, G-CSF, and GM-CSF were obtained from groups of healthy full-term infants at 0 (cord blood or nursery admission), 12, 24, 48, and 72 h. Samples were also obtained from premature infants at the above times and at 1 week. G-CSF and GM-CSF levels were measured using bioassays. Results: Levels of G-CSF ranged from <5 to 53,800 pg/ml. Levels were significantly higher (p < 0.001) in premature infants and decreased over time in all infants. White blood cell counts also decreased over the first week of life. All GM-CSF levels were below the detectable range. Conclusions: Levels of G-CSF at birth are higher than those seen in adults. These increased levels may partially explain the leukocytosis seen in the first week of life. This, as has been shown in preliminary studies, suggests that infants are capable of an increase in neutrophil count after administration of exogenous G-CSF.
引用
收藏
页码:176 / 179
页数:4
相关论文
共 17 条
[1]  
Siegel J., McCracken G., Sepsis neonatorum, N Engl J Med, 304, (1981)
[2]  
Baley J.E., Stark E.K., Warkentin P.I., Et al., Buffy coat transfusions of neutropenic neonates with presumed sepsis: A prospective, randomized trial, Pediatrics, 80, pp. 712-720, (1987)
[3]  
Cairo M., Therapeutic implications of dysregulated colony-stimulating factor expression in neonates, Blood, 82, pp. 2269-2272, (1993)
[4]  
Dale D.C., Bonilla M.A., Davis M.W., Et al., A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia, Blood, 81, pp. 2496-2502, (1993)
[5]  
Furman W.L., Fairclough D.L., Huhn R.D., Et al., Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy, J Clin Oncol, 9, pp. 1022-1028, (1991)
[6]  
Gillan E., Sven Y., Stringham D., Et al., A randomized placebo-controlled phase I/II trial of rhG-CSF in newborns with presumed sepsis: Absence of toxicity and induction of significant neutrophilia and bone marrow storage and progenitor pools, Pediatr Res, 33, (1993)
[7]  
Laver J., Duncan E., Abboud M., Et al., High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates, J Pediatr, 116, pp. 627-632, (1990)
[8]  
Shimoda K., Okamura S., Harada N., Et al., Serum granulocyte colony-stimulating factor levels in umbilical cord blood of normal full-term neonates, Biomed Pharmucother, 46, pp. 337-341, (1992)
[9]  
Cairo M.S., Gillan E.R., Buzby J.S., Et al., Circulating steel factor (SLF) and G-CSF levels in preterm and term newborn and adult peripheral blood, Am J Pediatr Hematol Oncol, 15, pp. 311-315, (1993)
[10]  
Stute N., Santana V.M., Rodman J.H., Et al., Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children, Blood, 79, pp. 2849-2854, (1992)